Supplementary Table 1: EGFR mutations highlighted by small panels and by exome analysis, but not found by hotspot analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Exon | Nucleotide variation | Amino acid variation | Impact | Presumed clinical impact |
| 18 | c.2156G>C | p.(Gly719Ala) | Activating | Sensitivity to Afatinib and Osimertinib |
| 20 | c.2303G>T | p.(Ser768I) | Activating | Sensitivity to Afatinib and Osimertinib |
| 20 | c.2305G>T | p.(Val769Leu) | Activating | Resistance to EGFR TKI |
| 20 | c.2310\_2311insGGG | p.(Asp770\_Asn771insGly) | Activating | Resistance to EGFR TKI |
| 20 | c.2314\_2315insCCCACG | p.(Pro772\_His773insHisAla) | Activating | Resistance to EGFR TKI |
| 21 | c.2494C>T | p.(Arg832Cys) | Activating | Unknown |
| 21 | c.2518G>A | p.(Ala840Thr) | Unknown | Unknown |
| 21 | c.2573T>G | p.(Leu858Arg) | Activating | Sensitivity to EGFR TKI |
| 23 | c.2749G>A | p.(Gly917Arg) | Unknown | Unknown |

TKI: Tyrosine Kinase Inhibitors